{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035993","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2026-08-04T20:05:47+00:00","discovered_at":"2026-08-04T20:07:00.223737+00:00","generated_at":"2026-08-04T20:07:27.535969+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Mangoceuticals gets Nasdaq bid-price extension to Feb 1, 2027; notes Nuclea Energy deal","bullets":["Nasdaq granted 180-day extension until Feb 1, 2027 to meet $1 minimum bid price for 10 consecutive days.","Company meets all other Nasdaq listing requirements except the bid price rule.","Company may effect a reverse stock split if needed to cure the deficiency.","Company continues to advance business combination with Nuclea Energy Inc. (Morpheus microreactor)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035993","json":"https://secwatch.observer/filing/0001493152-26-035993.json","markdown":"https://secwatch.observer/filing/0001493152-26-035993.md","text":"https://secwatch.observer/filing/0001493152-26-035993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315226035993/0001493152-26-035993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315226035993/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:07:27.535969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}